Business
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
CollPlant Biotechnologies (Nasdaq: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity","length":229,"tagName":"p","attribs":{}},{"type":"text","content":"Recently received a $2 million development payment from AbbVie","length":62,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call to be held today at 10:00 a.m. U.S. EDT","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.","length":375,"tagName":"p"},{"type":"image","alt":"CollPlant announces six-month study data from its regenerative breast implant program, which uses a 200cc commercial-size bioprinted breast implant (in front).","displaySize":"","headline":null,"caption":"CollPlant announces six-month study data from its regenerative breast implant program, which uses a 200cc commercial-size bioprinted breast implant (in front).","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":309,"url":"https://media.zenfs.com/en/prnewswire.com/3baa38c8d7a375e8d7b1f5922a043851"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nQx13Tl3YJKgNZJy0zAvaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3baa38c8d7a375e8d7b1f5922a043851","width":400,"height":309}},"href":"https://mma.prnewswire.com/media/2650539/CollPlant_200cc_BI.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This past year to date, we have progressed on all fronts - from advancing our collaborative programs, to gaining momentum on our proprietary programs as well as our marketed products. Specifically, we leveraged additional preclinical studies findings, refined a commercial design of our regenerative breast implants, gained an additional U.S. patent related to our photocurable dermal filler and also broadened the distribution network for our commercial product, Vergenix S...